Key Points
Pfizer's stock is down over 60% from its December 2021 peak (as of Aug. 1).
A drop in COVID-19 vaccines and treatment has caused a drop in Pfizer's revenue.
Pfizer's stock appears to be in bargain territory for long-term investors.
Five years ago, the world was in the thick of the COVID-19 global pandemic, bringing Pfizer (NYSE: PFE) into the spotlight because of the role it played in developing the COVID-19 vaccine with its partner BioNTech. It was able to get U.S. Food and Drug Administration (FDA) approval for its COVID-19 vaccine on Dec. 11, 2020, and it was released on Dec. 14, 2020.
Image source:???
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
From mid-2020 to late 2021, Pfizer's stock skyrocketed, but since hitting its peak, it has reversed course. Had you invested $1,000 into Pfizer's stock on Aug. 1, 2020, your investment would only be worth around $638 as of Aug. 1, 2025. Pfizer's dividend would've cushioned some of the blow, but an investment then would still be less than your initial investment, at $828.
PFE data by YCharts
Why has Pfizer's stock struggled the past few years?
Much of Pfizer's stock price troubles since hitting its Dec. 21 peak come down to a decline in demand for its COVID-19 vaccine and treatments, anticipated patent expirations on drugs like Ibrance (breast cancer) and Eliquis (blood clots), and an underwhelming pipeline. All isn't lost with Pfizer's stock, however.
At its current levels -- trading at 7.7 times forward earnings -- Pfizer seems to be flirting with bargain territory. I don't expect a quick turnaround, but this low valuation gives it more long-term upside than downside. It also helps that the stock's dividend yield sits above 7.3%, more than 5.5 times the S&P 500 average.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,064,820!*
Now, it’s worth noting Stock Advisor’s total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 4, 2025
Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy.